A director's $11.5 million open-market purchase is a strong bullish signal, especially after a large equity grant round. Monitor for upcoming clinical data readouts or partnership announcements that may have motivated this insider's conviction.
Price Chart
Executive Summary
Director Evan Lockwood Rachlin made a single open-market purchase of 718,800 shares of Iambic Therapeutics at $16.00/share, totaling $11.5 million. This conviction buy by a director, occurring shortly after a large equity grant cluster to all executives and directors, signals strong insider alignment and confidence in the company's prospects.
Key Financial Metrics
Key Facts
- Director Evan Lockwood Rachlin purchased 718,800 shares on the open market at $16.00/share, totaling $11.5 million.
- The purchase is a single, open-market transaction (code P) by a director, representing a material conviction buy.
- The purchase follows a cluster of equity grants to all directors and executives on October 14, 2026, totaling over 2.5 million shares at $0 (non-cash).
- The $11.5 million purchase is significant relative to the company's likely market cap, exceeding the 0.5% materiality threshold.
Financial Impact
Director purchased $11.5 million of common stock at $16.00/share, a material insider buy for a clinical-stage biotech.
Risk Factors
- The purchase is by a director, not a C-suite executive, which carries slightly less informational weight than a CEO/CFO buy.
- The company is a clinical-stage biotech with no approved products, so stock performance depends on pipeline execution.
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0002151678-26-000007 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | Insider Buy | $16.01 $15.80 | ▼ −1.31% | ▼ −1.84% | $14.41 (−9.99%) |
Oct 16, 2026 10d ago | 8-K | $16.34 $16.01 | ▼ −2.02% | ▼ −2.35% | $14.41 (−11.81%) |
Oct 15, 2026 11d ago | 424B4 | $23.81 $16.34 | ▼ −31.37% | ▼ −31.80% | $14.41 (−39.48%) |
Oct 15, 2026 11d ago | EFFECT | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
Oct 14, 2026 11d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
Oct 14, 2026 11d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
Oct 14, 2026 11d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
Oct 14, 2026 11d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
Oct 14, 2026 11d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
Oct 14, 2026 11d ago | 3 | $18.91 $23.81 | ▲ +25.91% | ▲ +27.02% | $14.41 (−23.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers